Back to search results

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

AL Amyloidosis · Amyloidosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States

    Contact: Study coordinator (Muhamed Baljevic, MD) · muhamed.baljevic@vumc.org · 615-936-8422
    Contact: Principal Investigator (Muhamed Baljevic, MD)

  • UT Southwestern Medical Center, Dallas, Texas, United States

    Contact: Study coordinator (Dongalan Xia) · donglan.xia@utsouthwestern.edu · 214-648-9079
    Contact: Principal Investigator (Larry Anderson, MD)

  • Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States

    Contact: Study coordinator (Nicole Fisher, MS) · nicole.fisher@hci.utah.edu · 801-587-7604
    Contact: Principal Investigator (Amandeep Godara, MBBS)
Study leads

  • Larry Anderson, MD

    Principal Investigator

    University of Texas Southwestern Medical Center

View source on ClinicalTrials.gov(opens in a new tab)